Infectious Disease In Vitro Diagnostics Market Size, Trends & Growth Opportunity By Product Type (ELISA-Based Assays, CLIA, Rapid Diagnostic Tests, PCR & RT-PCR Assays, Multiplex Molecular Panels, Point-of-Care Testing Kits), By Test Type (Serology, Molecular Diagnostics, Antigen-Based Testing, Culture-Based Diagnostics), By Disease Area (Viral, Bacterial, Parasitic, Emerging & Re-emerging Infections), By Laboratory Setting, By Customer Segment, and By Region and Forecast Till 2030

Market Overview & Definition

The global infectious disease in vitro diagnostics market is entering a phase of steady, service-driven expansion rather than the crisis-fueled surges that defined the pandemic years. Valued at an estimated $26.5 billion in 2025, the market is projected to reach approximately $30.0 billion by 2030, advancing at a compound annual growth rate of 2.5% across the forecast window.

In vitro diagnostics, or IVD, refers to tests performed on samples such as blood, saliva, or tissue outside the human body to detect pathogens, antibodies, or antigens associated with infection. For infectious disease applications specifically, this spans everything from decades-old ELISA immunoassays to next-generation multiplex molecular panels capable of screening for a dozen pathogens from a single sample.

Growth in this base year period is measured rather than explosive, and that is itself a meaningful signal. Demand has normalized after the extraordinary testing volumes of 2020 through 2022, settling into a pattern driven by routine screening programs, an aging population more susceptible to infection, rising tuberculosis and hepatitis burden in emerging markets, and continued replacement of manual assays with automated, higher-throughput platforms. For manufacturers and investors, this steadier growth curve rewards operational efficiency and platform breadth over one-time pandemic-driven capacity expansion.

The scope of this report spans reagents, kits, instruments, and testing services used specifically for infectious disease detection, distinguishing this category from the broader in vitro diagnostics market that also serves oncology, cardiology, and other clinical applications. The sections below break down the market across six segmentation lenses: product type, test type, disease area, laboratory setting, customer segment, and region.

Market Dynamics: Key Drivers, Restraints & Opportunities

Three forces are reshaping demand patterns in this market. Rising global infectious disease burden remains the foundational driver. Tuberculosis, hepatitis B and C, HIV, and antimicrobial-resistant bacterial infections continue to generate sustained testing volume across both high-income and emerging economies, and WHO-backed screening initiatives in the latter are expanding the addressable testing population each year. Layered on top of this baseline, an aging global population is proving more susceptible to opportunistic and hospital-acquired infections, adding incremental volume to routine hospital and reference laboratory testing menus.

Restraints are equally real. Reimbursement pressure in mature markets is compressing per-test pricing, particularly for high-volume serology and antigen assays that have become commoditized since 2022. Regulatory tightening, especially the European IVDR transition, has lengthened product certification timelines and raised compliance costs for manufacturers bringing new assays to market.

Opportunity is concentrated where testing technology intersects with decentralization. Point-of-care and near-patient testing formats are opening demand outside the traditional central laboratory, while multiplex molecular panels are converting what used to be several separate test orders into a single reimbursable procedure. For suppliers, the strategic question is no longer whether to invest in molecular and point-of-care capability, but how quickly that investment can be converted into a defensible catalog position before consolidation narrows the competitive field further. Our full report's opportunity assessment maps these openings against buyer procurement behavior in far greater depth than is possible here.

Market Segmentation by Product Type

The market divides into six product categories, each reflecting a different generation of testing technology and a different growth trajectory. PCR and RT-PCR assays represent the largest single product segment, accounting for an estimated 29% of 2025 revenue. Their dominance reflects the diagnostic gold-standard status molecular amplification holds for viral load monitoring, hepatitis genotyping, and outbreak-response testing, use cases where sensitivity outweighs cost sensitivity. CLIA-based chemiluminescence immunoassays follow at roughly 22% share, valued in high-throughput hospital and reference laboratory settings for automated, walk-away serology testing.

ELISA-based assays, the long-standing workhorse of infectious disease serology, still command approximately 18% of the market despite decades of technological evolution around them, a durability explained in greater technical depth on this site's testing technologies and methods resource. Rapid diagnostic tests hold close to 16% share and remain essential wherever laboratory infrastructure is limited or results are needed within minutes rather than hours. Multiplex molecular panels, though currently a smaller 10% slice of the market, are growing at close to 5.5% CAGR, the fastest of any product category, as laboratories consolidate pathogen panels to reduce per-sample turnaround time and reagent cost. Point-of-care testing kits round out the segmentation at approximately 5% share, a figure that understates their strategic importance given their role in extending testing into decentralized and outbreak-response settings.

This bifurcation between a large, mature immunoassay base and a smaller but fast-growing molecular and point-of-care tier is the single most important structural feature of the product landscape, and it is reshaping how suppliers allocate research and development budget across their portfolios.

Market Segmentation by Test Type

Beyond product platform, the market can be viewed through the lens of testing method. Molecular diagnostics, encompassing nucleic acid amplification and sequencing-based approaches, represents the largest test-type segment at an estimated 38% of revenue, a share that has grown steadily since 2020 as laboratories invested in PCR and multiplex infrastructure that has since found permanent use beyond respiratory panels.

Serology testing, detecting IgG, IgM, and IgA antibody responses, holds approximately 30% share and remains central to surveillance testing, blood bank screening, and retrospective exposure assessment, use cases where antibody kinetics matter more than immediate pathogen detection. Antigen-based testing accounts for roughly 22% of the market, valued for speed in acute infection scenarios where a positive result needs to be actionable within minutes. Culture-based diagnostics, the oldest method in the category, retains close to 10% share, concentrated in bacterial identification and antimicrobial susceptibility testing where culture remains the definitive confirmatory method despite slower turnaround.

The practical implication for buyers is that no single test type is displacing the others outright. Instead, laboratories are layering methods, using rapid antigen or molecular screening at the front end and reserving culture for confirmation and resistance profiling, a workflow pattern that is quietly reshaping instrument and reagent purchasing across hospital and reference laboratory budgets.

Market Segmentation by Disease Area

Viral infections constitute the largest disease-area segment, representing an estimated 45% of market revenue, driven by sustained testing demand across HIV, hepatitis B and C, influenza, and residual COVID-19 surveillance testing. This scale reflects both the sheer global prevalence of viral disease and the breadth of technology, from ELISA to multiplex molecular panels, built specifically around viral targets, a mapping explored test by test on this site's disease area applications resource.

Bacterial infections account for approximately 30% of the market, with tuberculosis, sepsis, and sexually transmitted disease testing as the dominant sub-categories. Sepsis diagnostics in particular is an area of accelerating clinical urgency, since faster pathogen identification directly shortens time to appropriate antibiotic therapy in critically ill patients. Parasitic infection testing holds a smaller but stable 15% share, concentrated in regions with high malaria and neglected tropical disease burden. Emerging and re-emerging infectious diseases, a category capturing novel outbreak pathogens and diseases regaining clinical relevance, represent the remaining 10%, and it is this segment's outbreak-driven demand spikes that make procurement forecasting for public health buyers especially difficult to model using standard replacement-cycle logic.

For manufacturers, disease-area segmentation is less about which category is largest today and more about which categories reward platform flexibility, since the same molecular chassis can often be reconfigured across viral, bacterial, and emerging pathogen targets with the right assay development investment.

Market Segmentation by Laboratory Setting & Customer Segment

Testing volume flows through four distinct laboratory environments. Central laboratories process the largest share of samples, at an estimated 35% of testing volume, owing to their automation scale and batch-testing economics. Hospital-based laboratories follow closely at roughly 30%, reflecting the need for rapid in-house turnaround on acutely ill patients. Reference laboratories account for about 20% of volume, typically handling specialized or lower-volume esoteric testing referred from smaller facilities, while point-of-care and decentralized testing environments represent the remaining 15%, a share that has grown steadily as testing moves closer to the patient, a shift covered in detail on this site's end users and laboratory settings resource.

Layered against these physical settings is customer segment, or who is actually purchasing the tests. Hospitals and healthcare providers are the largest buyer group at an estimated 40% of demand, followed by diagnostic laboratories and chains at roughly 28%. Public health agencies represent about 18% of demand, a share driven heavily by government screening and surveillance programs rather than individual clinical orders. Research institutes and academic labs account for approximately 9%, and blood banks and screening centers make up the remaining 5%, concentrated in transfusion-safety testing.

Understanding both dimensions together, not just who buys but where the test is physically run, is essential for suppliers deciding whether to prioritize high-throughput central laboratory platforms or compact, ruggedized point-of-care instruments in their next product cycle.

Regulatory & Certification Snapshot

Regulatory posture varies meaningfully by geography, and it is increasingly a determinant of competitive positioning rather than a background compliance cost. In Europe, the In Vitro Diagnostic Regulation, or IVDR, has raised classification and conformity-assessment requirements substantially compared with the previous IVD Directive, extending certification timelines for manufacturers bringing new infectious disease assays to market. In the United States, FDA clearance or approval pathways continue to govern market access, with Emergency Use Authorization precedent from the pandemic period still shaping how regulators approach accelerated review for outbreak-relevant tests. A closer walk-through of each pathway, including how requirements differ by region, is available on this site's regulatory and certification landscape resource.

Beyond these two anchor jurisdictions, WHO Prequalification carries particular weight for suppliers targeting public health procurement in lower-income markets, since many multilateral and government tenders require prequalified status as a bid condition. ISO 13485 quality management certification and ISO 15189 laboratory accreditation round out the compliance landscape, the former governing manufacturers and the latter governing the laboratories running the tests.

For manufacturers evaluating where to launch next, regulatory readiness is now a genuine source of competitive advantage. Companies that treat IVDR and FDA submission timelines as parallel workstreams rather than sequential ones are reaching new markets meaningfully faster than peers who are not.

Leading Companies Snapshot

The competitive landscape is structured in three broad tiers. A small group of global diagnostics majors, including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, and Thermo Fisher Scientific, together account for an estimated 48% of global revenue, built on broad product portfolios spanning immunoassay, molecular, and point-of-care platforms alongside extensive direct sales and distribution infrastructure.

A second tier of molecular and specialty diagnostics players, among them QIAGEN, DiaSorin, bioMérieux, and Bio-Rad Laboratories, competes on technology depth rather than portfolio breadth, often leading in specific assay categories even where they lack the global majors' scale. Point-of-care and hematology-adjacent specialists such as Sysmex Corporation and Becton Dickinson occupy a distinct niche built around decentralized and near-patient testing formats. Below these tiers sit a longer roster of regional and application-specific specialists, including serology-focused manufacturers like Institut Virion Serion, that compete on formulation depth and regional service relationships rather than global scale, a positioning profiled company by company on this site's leading companies and manufacturers resource.

This tiered structure matters strategically because it is not static. Consolidation activity among mid-tier molecular players continues to reshape the competitive map, and our full report's competitive benchmarking tracks exactly how market share has shifted across these tiers over the past three years.